Shravan Asthana

Mr. Shravan Asthana

Pennsylvania State University, State College, Pennsylvania, USA
orcid
Northwestern Feinberg School of Medicine

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2022 in Cells
Verified
Journal Article
Open access
PDF file
Shravan AsthanaShravan Asthana
Shravan Asthana
Hannah MartinHannah Martin
Hannah Martin
Julian RupkeyJulian Rupkey
Julian Rupkey
SPShray Patel
Shray Patel
JYJoy Yoon
Joy Yoon
YMYingwei Mao
Yingwei Mao
The exon junction complex (EJC) becomes an increasingly important regulator of early gene expression in the central nervous system (CNS) and other tissues. The EJC is comprised of three core proteins: RNA-binding motif 8A (RBM8A), Mago homolog (MAGOH), eukaryotic initiation factor 4A3 (EIF4A3), and a peripheral EJC factor, metastatic lymph node 51 (MLN51), together with various auxiliary factors. The EJC is assembled specifically at exon-exon junctions on mRNAs, hence the name of the complex. The EJC regulates multiple levels of gene expression, from splicing to translation and mRNA degradation. The functional roles of the EJC have been established as crucial to the normal progress of embryonic and neurological development, with wide ranging implications on molecular, cellular, and organism level function. Dysfunction of the EJC has been implicated in multiple developmental and neurological diseases. In this review, we discuss recent progress on the EJC’s physiological roles.

Verified
Journal Article
Open access
PDF file
Hannah MartinHannah Martin
Hannah Martin
Julian RupkeyJulian Rupkey
Julian Rupkey
Shravan AsthanaShravan Asthana
Shravan Asthana
JYJoy Yoon
Joy Yoon
SPShray Patel
Shray Patel
YMYingwei Mao
Yingwei Mao
The exon junction complex (EJC) plays a crucial role in regulating gene expression at the levels of alternative splicing, translation, mRNA localization, and nonsense-mediated decay (NMD). The EJC is comprised of three core proteins: RNA-binding motif 8A (RBM8A), Mago homolog (MAGOH), eukaryotic initiation factor 4A3 (eIF4A3), and a peripheral EJC factor, metastatic lymph node 51 (MLN51), in addition to other peripheral factors whose structural integration is activity-dependent. The physiological and mechanistic roles of the EJC in contribution to molecular, cellular, and organismal level function continue to be explored for potential insights into genetic or pathological dysfunction. The EJC’s specific role in the cell cycle and its implications in cancer and neurodevelopmental disorders prompt enhanced investigation of the EJC as a potential target for these diseases. In this review, we highlight the current understanding of the EJC’s position in the cell cycle, its relation to cancer and developmental diseases, and potential avenues for therapeutic targeting.

22 November 2023 in Cancers
Verified
Journal Article
Open access
PDF file
DFDavid Jun Fei-Zhang
David Jun Fei-Zhang
EEEvan R. Edwards
Evan R. Edwards
Shravan AsthanaShravan Asthana
Shravan Asthana
DCDaniel C. Chelius
Daniel C. Chelius
ASAnthony M. Sheyn
Anthony M. Sheyn
JRJeffrey C. Rastatter
Jeffrey C. Rastatter
Background: There is currently no comprehensive tool that quantifiably measures validated factors of modern technology access in the US for digital inequity impact on esophageal cancer care (EC). Objective: To assess the influence of digital inequities on esophageal cancer disparities while accounting for traditional social determinants. Methods: 15,656 EC patients from 2013–2017 in SEER were assessed for significant regression trends in long-term follow-up, survival, prognosis, and treatment with increasing overall digital inequity, as measured by the Digital Inequity Index (DII). The DII was calculated based on 17 census tract-level variables derived from the American Community Survey and Federal Communications Commission. Variables were categorized as infrastructure access or sociodemographic, ranked, and then averaged into a composite score. Results: With increasing overall digital inequity, significant decreases in the length of long-term follow-up (p < 0.001) and survival (p < 0.001) for EC patients were observed. EC patients showed decreased odds of receiving indicated surgical resection (OR 0.97, 95% CI 0.95–99) with increasing digital inequity. They also showed increased odds of advanced preliminary staging (OR 1.02, 95% CI 1.00–1.05) and decreased odds of receiving indicated chemotherapy (OR 0.97;95% CI 0.95–99). Conclusions: Digital inequities meaningfully contribute to detrimental trends in EC patient care in the US, allowing discourse for targeted means of alleviating disparities while contextualizing national, sociodemographic trends of the impact of online access on informed care.

13 March 2024 in Cells
Verified
Journal Article
Open access
PDF file
Shravan AsthanaShravan Asthana
Shravan Asthana
JMJennifer Mott
Jennifer Mott
MTMabel Tong
Mabel Tong
ZPZifei Pei
Zifei Pei
YMYingwei Mao
Yingwei Mao
The role of RNA Binding Motif Protein 8a (RBM8A), an exon junction complex (EJC) component, in neurodevelopmental disorders has been increasingly studied for its crucial role in regulating multiple levels of gene expression. It regulates mRNA splicing, translation, and mRNA degradation and influences embryonic development. RBM8A protein is expressed in both neurons and astrocytes, but little is known about RBM8A’s specific role in glial fibrillary acid protein (GFAP)-positive astrocytes. To address the role of RBM8A in astrocytes, we generated a conditional heterozygous knockout (KO) mouse line of Rbm8a in astrocytes using a GFAP-cre line. We confirmed a decreased expression of RBM8A in astrocytes of heterozygous conditional KO mice via RT-PCR and Sanger sequencing, as well as qRT-PCR, immunohistochemistry, and Western blot. Interestingly, these mice exhibit significantly increased movement and mobility, alongside sex-specific altered anxiety in the open field test (OFT) and elevated plus maze (OPM) tests. These tests, along with the rotarod test, suggest that these mice have normal motor coordination but hyperactive phenotypes. In addition, the haploinsufficiency of Rbm8a in astrocytes leads to a sex-specific change in astrocyte density in the dentate gyrus. This study further reveals the contribution of Rbm8a deletion to CNS pathology, generating more insights via the glial lens of an Rbm8a model of neurodevelopmental disorder.

25 April 2025 in JCO Oncology Practice
Verified
Journal Article
Closed access
JDJalpa A. Doshi
Jalpa A. Doshi
PLPengxiang Li
Pengxiang Li
Shravan AsthanaShravan Asthana
Shravan Asthana
JLJohn K. Lin
John K. Lin
PURPOSE: Medicare Part D beneficiaries who do not qualify for low-income subsidies face high out-of-pocket (OOP) costs for brand-name specialty oral anticancer medications (SOAMs). We calculated how OOP costs for such SOAMs might evolve on the basis of the Inflation Reduction Act’s (IRA) Part D benefit changes. METHODS: We calculated OOP costs for 10 commonly used brand-name SOAMs across various cancers under four Part D benefit scenarios: (1) 2023: before IRA implementation (pre-IRA), (2) 2024: an annual OOP maximum set at the catastrophic threshold during initial IRA implementation (mid-IRA), (3) 2025: an annual OOP maximum set at $2,000 in US dollars (USD) after final IRA implementation (post-IRA, default), and (4) 2025: $2,000 USD annual OOP maximum and voluntary enrollment in the Medicare Prescription Payment Plan (MPPP) to smooth OOP costs via monthly payments (post-IRA, opt-in MPPP). RESULTS: In 2023 (pre-IRA), annual OOP costs for SOAMs ranged from $11,143 USD to $20,592 USD. In 2024 (mid-IRA) and 2025 (post-IRA), beneficiaries would only pay the new OOP maximums of $3,333 USD and $2,000 USD, respectively, regardless of SOAM prescribed or treatment duration. In 2025, the $2,000 USD OOP amount would be entirely frontloaded in January unless beneficiaries enroll in the MPPP, which could lower their OOP costs to just $167 USD for January and each calendar month thereafter, regardless of SOAM prescribed or treatment duration. CONCLUSION: Although the annual OOP maximum enacted by the IRA will decrease OOP costs significantly for Medicare beneficiaries treated with brand-name SOAMs beginning 2025, enrollment in the MPPP is critical to avoid patients owing the entire $2,000 USD in January alone. Oncology providers have a critical role to play in ensuring beneficiaries are aware of the option to smooth their OOP costs via MPPP enrollment.

30 August 2024 in The Joint Commission Journal on Quality and Patient Safety
Verified
Journal Article
Open access
Shravan AsthanaShravan Asthana
Shravan Asthana
LGLuis Gago
Luis Gago
JGJoshua Garcia
Joshua Garcia
MBMolly Beestrum
Molly Beestrum
TPTeresa Pollack
Teresa Pollack
MGMita Sanghavi Goel
Mita Sanghavi Goel
Background: Housing instability in the United States is a critical social determinant of health, influencing health outcomes and healthcare utilization. This scoping review aimed to analyze literature on US health system screening and response programs addressing housing instability, highlighting methodologies, geographic and demographic variations, and policy implications. Methods: Adhering to PRISMA-ScR guidelines, the review included studies focusing on US health systems that screen and refer for housing instability. Major scholarly databases including PubMed and Scopus were queried. Screening and response program characteristics, methodologies, and outcomes were characterized. Results: Thirty studies published between 2003 and 2023 were included in this study. Included studies were primarily cross-sectional (23.3%) or quality improvement (20.0%), among eleven other designs. Screening programs were predominantly implemented in academic hospital systems (46.7%), in the Northeast (63.3%), and in outpatient settings (68.0%), and the majority used electronic health record entry (52.2%). Of the 22 studies that described their screening tool, 15 used institution-specific tools and only four of the remaining seven studies used identical tools. Of the 20 studies that described their response to positive screenings, 13 provided patients with a paper or electronic referral to a collaborating community partner while only six aided the patient in connecting with community resources. Conclusions: This study found significant variability in screening and response programs for housing instability among US healthcare providers. A lack of standardized definitions and methodologies hampers effective comparison and implementation of these programs. Future research should focus on standardizing screening methods and measurement of interventions and outcomes to address housing instability.